You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

300 Results
Guidelines and Advice
Status: Current
ID: GL 8-12
Updated
Jan 2026
Guidelines and Advice
Status: Current
ID: 7-11
Version: 3
Mar 2022
Regimen
Cancer Type:
Central Nervous System
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    vorasidenib - For the treatment of Grade 2 astrocytoma or oligodendroglioma in patients with a susceptible IDH1 mutation or IDH2 mutation following surgery, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
vorasidenib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2026
Guidelines and Advice
Status: Archived
ID: SCT 6
Feb 2016
Drug
Other Name(s): Zolinza®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Mar 2026
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
sevabertinib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
New
Apr 2026
Drug
Other Name(s): Voranigo™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Apr 2026
The following information answers many of the questions primary care physicians commonly ask about the Screening Activity Report and the included...

Pages